Discover
GRCE
Grace Therapeutics, Inc.
2.43
5 x 2.26
2 x 2.67
bid
ask
+
0.00
0.00%
1 @ 04:00 PM
2.42 -0.01 (0.21%)
| Ytd | -29.77% | |
| 1y | -28.32% |
2.41
day range
2.48
1.79
52 week range
5.18
| Open | 2.43 | Prev Close | 2.43 | Low | 2.41 | High | 2.48 | Mkt Cap | 39.55M |
| Vol | 94.31K | Avg Vol | 496.96K | EPS | -0.57 | P/E | -4.26 | Forward P/E | -2.90 |
| Beta | 0.37 | Short Ratio | 3.25 | Inst. Own | 21.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-20 | 50-d Avg | 2.35 | 200-d Avg | 3.23 | 1yr Est | 10.44 |
GRCE News
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
benzinga.com
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analy
benzinga.com
TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8
TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the pr
benzinga.com
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no
benzinga.com
Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Req
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, an
benzinga.com
Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safe
The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analy